Minerva Neurosciences Inc (NERV)

Minerva Neurosciences' stock price increased by 146.66% over the past six months. In October 2025, the company secured up to $200 million in financing to advance roluperidone, resubmit its NDA, and prepare for a potential U.S. commercial launch. The FDA cleared the design for a confirmatory Phase 3 trial for roluperidone, causing the company's shares to surge by as much as 141% in a single day.

As a clinical-stage biopharmaceutical company, Minerva Neurosciences does not have traditional product demand seasonality. However, historical stock data suggests a seasonal pattern with a "Buy Date of April 24 and a Sell Date of September 18" yielding positive average returns. This aligns with the broader Healthcare sector's seasonal trend.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) diseases, operating within the Healthcare sector, specifically in the Biotechnology and Pharmaceutical Products industry. Its major product candidates include Roluperidone (for schizophrenia), MIN-301 (for Parkinson's disease and other neurodegenerative disorders), Seltorexant (for insomnia and depressive disorders), and MIN-117 (for major depressive disorder).

Minerva Neurosciences, Inc. is headquartered in Burlington, Massachusetts, and incorporated in Delaware. The company conducts research within the United States and collaborates with global academic partners and contract research organizations.

Minerva Neurosciences' brand reputation has been bolstered by positive developments related to roluperidone. The announcement of a financing deal and FDA alignment on a Phase 3 trial design led to positive press and bullish sentiment among retail traders. There were no explicit negative events impacting its reputation mentioned in the past year.

Minerva Neurosciences' stock is primarily owned by institutional investors and insiders. As of September 2025, institutional ownership stood at 24.55% to 26.1% of total outstanding shares. Major institutional shareholders include Federated Hermes, Inc., The Vanguard Group, Inc., and BlackRock, Inc. Significant individual and insider owners include Index Venture Associates III Ltd, Care Capital III LLC, and Michele Ollier.